In obesity, vanillic acid acts by inhibiting adipogenesis markers PPARγ and C/EBPα, activating the AMPK signaling pathway, reducing lipid accumulation and inflammation, promoting thermogenesis, enhancing glucose tolerance, and improving insulin resistance. Here, CEBPA is linked to obesity due to melanocortin 4 receptor deficiency.